News

PublISHED ON 11 October 2018

UpDATED ON 16 October 2018

Research funding available for next-generation biologics

The Swedish Research Council and Vinnova have formulated a national programme for protein research, method development and production of biologics. It is now possible to apply for up to 10 million SEK for protein research and process development for biologics. The call closes January 15, 2019. 

The programme is a part of the government’s strategic investment in life science aiming to promote better health, face societal challenges, strengthen Sweden’s position as a leading country for research and development, and increase Sweden’s competitiveness in an international perspective.

The programme contains both protein research for biologics, as well as development of more efficient methods for next-generation production of biologics. The programme runs from 2016 to 2023 and comprises 320 million SEK in total.

A call for protein research and process development for biologics is now open and closes January 15, 2019.

You can find all the information (in Swedish) about the call on Vinnova’s websiteexternal link.

Copied to clipping

PUBLISHED ON 11 October 2018

UpDATED ON 16 October 2018

Copied to clipping


MORE WITHIN THE SAME SUBJECT AREA

  1. Millions to strengthen health care science

    Seven research programmes are awarded funding from the Swedish Research Council and Forte to improve and develop healthcare. Between them, the programmes will be sharing SEK 100 million over three years, with the possibility of a three-year extension...

  2. 90 million SEK to research infrastructure for clinical studies

    The Committee for Clinical Studies has decided to allocate 90 million SEK to the continuing work of building up a joint national research infrastructure for clinical studies. During 2018–2020, 30 million SEK per year will be allocated. At the meeting...

  3. Research Project Grant for International Collaboration within Antimicrobial Resistance (JPIAMR)

    The publication date is preliminary.

Link to Twitter
Link to contact info page
Link to LinkedIn page